From the publishers of JADPRO

MPN Resource Center


TRANSFORM-1: A randomized, double-blind, placebo-controlled, multicenter, international phase 3 study of navitoclax in combination with ruxolitinib versus ruxolitinib plus placebo in patients with untreated myelofibrosis

Last Updated: Thursday, January 18, 2024

Data from the first randomized trial in JAK inhibitor–naïve intermediate-2 or high-risk myelofibrosis with navitoclax (NAV) plus ruxolitinib (RUX)—presented during the 2023 American Society of Hematology Annual Meeting—showed that the rate of spleen volume reduction of ≥35% at Week 24 was twice as high in the NAV + RUX group (63.2%) as the group receiving placebo plus RUX (31.5.%; P<0.0001). These responses were durable with median duration of response in the NAV + RUX group not reached compared with 19.4 months in patients on placebo plus RUX (95% CI: 16.8, NR). Hematologic adverse events were common but manageable with dose modifications.   

2023 American Society of Hematology Annual Meeting Abstract
News & Literature Highlights

British Journal of Haematology

‘MPN Genomic Calculator’: real‐life use in a young population with essential thrombocythaemia


Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN

Thrombosis Research

Patient outcomes in myeloproliferative neoplasm-related thrombosis: Insights from the National Inpatient Sample

British Journal of Haemtology

Real‐world non‐interventional long‐term post‐authorisation safety study of ruxolitinib in myelofibrosis

Cancer Medicine

Depressive symptoms and myeloproliferative neoplasms: Understanding the confounding factor in a complex condition

Expert Review of Hematology

Developing strategies to reduce the duration of therapy for patients with myeloproliferative neoplasms

European Society for Medical Oncology (ESMO) Congress 2021 Abstract

Final results of a phase II study of tipifarnib in chronic myelomonocytic leukemia (CMML) and other myelodysplastic/myeloproliferative neoplasms (MDS/MPN)

European Society for Medical Oncology (ESMO) Congress 2021 Abstract

Treatment outcomes and antibody immunity to SARS-CoV-2 in patients with hematological malignancies

Annals of Hematology

Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms

Clinical Lymphoma Myeloma and Leukemia

Mortality and causes of death of patients with polycythemia vera: analysis of the REVEAL prospective, observational study